Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice

Annals of Oncology

Volumn 12, Issue 3, 2001, Pages 405-410

  Langer, S W ^a,b   Sehested, M ^b   Buhl Jensen, P ^a  

^a FINSEN LABORATORY   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Anthracycline; Catalytic inhibitor; Dexrazoxane (ICRF 187); Extravasation; Free radical scavenger; Topoisomerase II

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; ACETYLCYSTEINE; ACLARUBICIN; ACLARUBICIN MEDAC; ALPHA TOCOPHEROL; AMIFOSTINE; ANTHRACYCLINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EDETIC ACID; HYPONORM; IDARUBICIN; MERBARONE; MIDAZOLAM MALEATE; RAZOXANE; SELEVITAN VET; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COOLING; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; WOUND; WOUND HEALING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; MICE; RAZOXANE; ULCER;

EID: 0035067840     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011163823321     Document Type: Article

References (32)

1. Prevention and management of extravasation of cytotoxic drugs
2. Antidotes to vesicant chemotherapy extravasations
3. Risk factors for doxorubicin-induced congestive heart failure
4. Risk factors for development of daunorubicin cardiotoxicity
5. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity
6. Dexrazoxane protects against anthracycline extravasation
7. Chemistry of dexrazoxane and analogues
8. Inhibition of intracellular topoisomerase II by antitumor bis(2, 6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors
9. Antagonistic effect of the cardioprotector (+)-1,2,-bis(3-5-dioxopiperazinyl-lyl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)
10. Inhibition of topoisomerase II by antitumor agents bis(2,6- dioxopiperazine) derivatives
11. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors
12. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide
13. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects
14. Cardioprotection of rat heart myocytes with amifostine (ethyol) and its free thiol, WR-1065, in vitro
15. Efficacy of amifostine for adriamycin extravasation injury
16. Temperature dependence studies of adriamycin uptake and cytotoxicity
17. Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse
18. Evaluation of dimethyl sulfoxide and local cooling as antidotes for doxorubicin extravasation in a pig model
19. Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics
20. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes
21. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells
22. Prevention of adriamycin-induced skin necrosis with various free radical scavengers
23. Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse
24. Pharmacologic antidotes to experimental doxorubicin skin toxicity: A suggested role for beta-adrenergic compounds
25. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone
26. Antagonistic effect of aclarubicin on daunorubicin induced cytotoxicity in human small-cell lung cancer cells: Relationship to DNA integrity and topoisomerase II
27. Catalytic inhibitors of DNA topoisomerase II
28. In vivo inhibition of etoposide-mediated apoptosis, toxicity and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin